ASHP Disappointed in MedPAC Recommendation to Congress on 340B
ASHP Disappointed in 340B Orphan Drug Court Decision
ASHP Letter Supporting Bill to Clarify Intent of 340B Program [PDF]
ASHP Statement for the Record: House Energy and Commerce Subcommittee on Health Hearing: Opportunities to Improve the 340B Drug Pricing Program"
ASHP Statement Effective Administration of the 340B Drug Pricing Program
ASHP Testimony: U.S. Senate Health, Education, Labor, and Pensions Committee Hearing: Perspectives on the 340B Drug Pricing Program
ASHP Issue Brief: Congress Releases 340B Report Including Potential Legislative Options
ASHP Opposes H.R. 4710, a Bill Restricting the 340B Program
ASHP Letter of Support for HR 4392
ASHP Supports Closing Loopholes for Orphan Drugs Act [PDF]
ASHP Statement: House Energy and Commerce Subcommittee on Health Hearing:Examining the 340B Drug Pricing Program [PDF]
ASHP Comments on OPPS Proposed Rule [PDF]
ASHP Comments on Draft 340B Omnibus Guidance [PDF]
Regulatory Alert-Proposed Guidance: 340B Discount Program [PDF]
Office of Inspector General Report on State Medicaid Policies and Oversight Activities Related to 340B-Purchased Drugs: Summary and Impact to ASHP [PDF]
We represent pharmacists who serve as patient care providers in acute and ambulatory settings.